Locally Advanced or Metastatic Prostate Cancer. Clinical Trial
Official title:
Depiction of Prostate Cancer Treatment Alternatives in Greece
| Verified date | October 2009 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Greece: National Organization of Medicines |
| Study type | Observational |
A retrospective, registry analysis of the socio-economic and demographic characteristics of
patients suffering from locally advanced or metastatic prostate cancer, as well as the
depiction of the therapeutic algorithms followed in the Greek clinical practice.
- Target Group: Patients with locally advanced or metastatic prostate cancer.
- The first 10 consecutive patients records that meet the entry criteria.
| Status | Completed |
| Enrollment | 310 |
| Est. completion date | March 2009 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Patients diagnosed with Locally advanced or Metastatic Prostate Cancer after 2002. - Patients that received Hormonal therapy. Exclusion Criteria: - Males that are aged less than 18 years |
Observational Model: Case-Only, Time Perspective: Retrospective
| Country | Name | City | State |
|---|---|---|---|
| Greece | Research Site | Athens | |
| Greece | Research Site | Karditsa | |
| Greece | Research Site | Serres | |
| Greece | Research Site | Xsanthi |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
Greece,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of patients treated by each treatment alternative. | Between 2002 - 2008 | ||
| Secondary | To depict sociodemographic characteristics and comorbidities. | Between 2002 - 2008 |